ONESOURCE

CDMO player, 'One Source' as provided, has also seen a significant correction, down 47% from its peak. Its Q3 FY26 performance was weak, with revenue dropping 26% and EBITDA a staggering 88%. A key factor was a semaglutide delay in Canada, coupled with broader sector headwinds like client inventory destocking and market skepticism around the Biocure Act and 'China Plus One' strategies. These factors point to significant near-term growth concerns, making it a challenging play for investors right now.